News

Gregory Demopulos: Thank you, Jennifer, and good afternoon, everyone. Joining me today are David Borges, our Chief Accounting Officer; Dr. Cathy Melfi, our Chief Regulatory Officer; and Dr. Steve Whitaker, Vice President of Clinical. After that, David will cover the financials in more detail and then we'll open the call for questions.

Moby summary of Omeros Corporation's Q1 2026 earnings call

Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. Chairman and Chief Executive

Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipeline and regulatory milestones, even as adjusted sales declined because of lower realized prices. Chi

Analysts initiated covered Tuesday of IPO stock Kailera Therapeutics, a potential competitor to Lilly and Novo in obesity treatment.

European stock markets fell in late Tuesday trading as oil prices rose after negotiations between th

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.5% and the actively tr

By Amina Niasse and Siddhi Mahatole May 11 (Reuters) - Hims & Hers Health missed Wall Street estimates for first-quarter revenue and posted a surprise loss on Monday, as the telehealth company's shift

The telehealth platform posted a quarterly loss of $92.1 million, driven by higher expenses, including those tied to operations, technology and general and administrative functions.

Switzerland’s Sandoz sees Canada and Brazil markets as testing grounds before semaglutide goes off patent in Europe and the U.S. in the 2030s.

Lexicon Pharmaceuticals (NASDAQ:LXRX) executives highlighted progress across late-stage regulatory programs and efforts to bolster the company’s financial position during the company’s first-quarter 2026 earnings call on May 7. Chief Executive Officer Mike Exton said the company entered 2026 with o

Novo now expects profit and sales declines of up to 12% this year, better than its earlier 13% forecast.

Find insight on Amazon Pharmacy, Sanofi, Sunway Health and more in the latest Market Talks covering the health care sector.

LONDON/COPENHAGEN, May 7 (Reuters) - Early data from weight-loss pills are lifting shares in Novo Nordisk and Eli Lilly as investors bet that easier-to-take drugs could expand the market to millions more patients and help counter pricing pressure. Denmark's Novo, ‌which has struggled to keep pace with U.

Novo Nordisk (NYSE:NVO) raised its 2026 full year guidance after the launch of its oral Wegovy weight loss pill in the U.S. Prescriptions for the oral version have surpassed 2,000,000 since January, signaling strong demand for the new format. The update comes during a period of intense competition with Eli Lilly and ongoing pricing pressures in the weight loss drug market. Novo Nordisk, trading at $45.76, sits at the center of the current weight loss drug story, with oral Wegovy adding a...

While investors obsess over uptake of GLP-1 pills in the U.S., international sales are just as important.

Shares of Novo Nordisk (NVO), the maker of the GLP-1 drug Wegovy, popped this morning after the company reported strong demand for its new weight-loss pill.Novo Nordisk President & CEO Mike Doustdar joined Julie Hyman on Opening Bid to discuss Q1 sales and the rest of the year guidance.

Novo Nordisk (NYSE:NVO) reported first-quarter results that far exceeded analyst estimates on Wednesday, driven by surging demand for its oral weight-loss pill and strong international sales. Net sales reached $15.2 billion in the quarter, well above the $11.2 billion analysts had...

Find insight on Novo Nordisk, Hartalega, Smith & Nephew and more in the latest Market Talks covering Health Care.

First-quarter sales of the oral Wegovy pill hit $353 million, more than double analyst expectations, as the company lifted its full-year outlook

Novo Nordisk stock rose as it raised its guidance on the back of the strong performance of its weight-loss pill.

Total prescriptions for the new Wegovy pill reached around 1.3 million in the first quarter and have exceeded 2 million since it launched.

Shares in Wegovy maker Novo Nordisk surged this morning after it reported strong demand for its new weight-loss pill and upgraded its guidance. The Danish drugmaker said total prescriptions for the Wegovy pill reached around 1.

May 6 (Reuters) - European shares rose on Tuesday, with oil prices dropping and investor optimism rising after U.S.

Total prescriptions for the Wegovy pill reached around 1.3 million in the first quarter and have exceeded 2 million since it launched.

COPENHAGEN, May 6 () - Novo Nordisk, the maker of weight-loss drug Wegovy, on Wednesday reported first-quarter revenue and adjusted operating profit above expectations and said its outlook ‌for the year was slightly improved. The Danish drugmaker is banking on demand for ‌its new weight-loss pill as competition with U.

First quarter earnings season is in full swing, with a full slate of semiconductor and consumer companies slated to report results.

ON Semiconductor, Pfizer, Uber, McDonald’s, and many more will report earnings this week. Economic releases will include the April jobs report and purchasing managers index.